Liposomal Doxorubicin Market
According to Intent Market Research, the Liposomal Doxorubicin Market is expected to grow from USD 1.3 billion in 2024-e at a CAGR of 7.0% to touch USD 2.1 billion by 2030. The Liposomal Doxorubicin Market is dominated by key players such as Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Novartis AG, Spectrum Pharmaceuticals, Lipocine Inc. and Mylan N.V. (now part of Viatris).